Literature DB >> 32886244

Emerging cancer therapies and cardiovascular risk.

Wendy Bottinor1,2, Amar Parikh3, Eiman Jahangir3.   

Abstract

The cardiovascular (CV) toxicity profiles of traditional cancer therapies such as anthracyclines and radiation therapy are familiar to many cardiologists. With the development and widespread use of additional cancer therapeutics, CV toxicities related to these agents are becoming more common. Cardiovascular specialists are often integrated into the care team for individuals with cancer and knowledge of the CV toxicities of cancer therapeutics has become essential. In this review, we provide a clinically focused summary of the current data regarding CV toxicities of common cancer therapies and identify potential management strategies for the CV specialist.

Entities:  

Keywords:  Androgen deprivation therapy; Cardio-oncology; Cardiovascular toxicity; Immune checkpoint inhibitors; Proteasome inhibitors; Tyrosine kinase inhibitors; Vascular endothelial growth factor inhibitors

Mesh：

Substances：

Year:  2021        PMID： 32886244     DOI： 10.1007/s11239-020-02263-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  41 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Authors:  Joe-Elie Salem; Ali Manouchehri; Melissa Moey; Bénédicte Lebrun-Vignes; Lisa Bastarache; Antoine Pariente; Aurélien Gobert; Jean-Philippe Spano; Justin M Balko; Marc P Bonaca; Dan M Roden; Douglas B Johnson; Javid J Moslehi
Journal:  Lancet Oncol       Date:  2018-11-12       Impact factor: 41.316

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 4.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

5.  Vasculitis associated with immune checkpoint inhibitors-a systematic review.

Authors:  Anisha Daxini; Keri Cronin; Antoine G Sreih
Journal:  Clin Rheumatol       Date:  2018-06-19       Impact factor: 2.980

6.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Authors:  Javid J Moslehi; Joe-Elie Salem; Jeffrey A Sosman; Bénédicte Lebrun-Vignes; Douglas B Johnson
Journal:  Lancet       Date:  2018-03-10       Impact factor: 79.321

7.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

8.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Authors:  Gerald P Linette; Edward A Stadtmauer; Marcela V Maus; Aaron P Rapoport; Bruce L Levine; Lyndsey Emery; Leslie Litzky; Adam Bagg; Beatriz M Carreno; Patrick J Cimino; Gwendolyn K Binder-Scholl; Dominic P Smethurst; Andrew B Gerry; Nick J Pumphrey; Alan D Bennett; Joanna E Brewer; Joseph Dukes; Jane Harper; Helen K Tayton-Martin; Bent K Jakobsen; Namir J Hassan; Michael Kalos; Carl H June
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

9.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

Review 10.  Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

Authors:  Ibrahim Aldoss; Samer K Khaled; Elizabeth Budde; Anthony S Stein
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.